188 related articles for article (PubMed ID: 36203656)
1. Molecular classification of human papillomavirus-positive cervical cancers based on immune signature enrichment.
Song G; Luo J; Zou S; Lou F; Zhang T; Zhu X; Yang J; Wang X
Front Public Health; 2022; 10():979933. PubMed ID: 36203656
[TBL] [Abstract][Full Text] [Related]
2. Subtyping of Human Papillomavirus-Positive Cervical Cancers Based on the Expression Profiles of 50 Genes.
Zhu X; Li S; Luo J; Ying X; Li Z; Wang Y; Zhang M; Zhang T; Jiang P; Wang X
Front Immunol; 2022; 13():801639. PubMed ID: 35126391
[TBL] [Abstract][Full Text] [Related]
3. Gene set enrichment analysis identifies immune subtypes of kidney renal clear cell carcinoma with significantly different molecular and clinical properties.
Chen Z; Cao W; Luo J; Abdelrahman Z; Lu Q; Wang H; Wang X
Front Immunol; 2023; 14():1191365. PubMed ID: 37426638
[TBL] [Abstract][Full Text] [Related]
4. Identifying Immune-Specific Subtypes of Adrenocortical Carcinoma Based on Immunogenomic Profiling.
Lu Q; Nie R; Luo J; Wang X; You L
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671489
[TBL] [Abstract][Full Text] [Related]
5. HPV-related methylation-based reclassification and risk stratification of cervical cancer.
Yang S; Wu Y; Wang S; Xu P; Deng Y; Wang M; Liu K; Tian T; Zhu Y; Li N; Zhou L; Dai Z; Kang H
Mol Oncol; 2020 Sep; 14(9):2124-2141. PubMed ID: 32408396
[TBL] [Abstract][Full Text] [Related]
6. Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated with Human Papillomavirus Type 16 Expression, Molecular Features, and Clinical Outcome.
Lu X; Jiang L; Zhang L; Zhu Y; Hu W; Wang J; Ruan X; Xu Z; Meng X; Gao J; Su X; Yan F
Neoplasia; 2019 Jun; 21(6):591-601. PubMed ID: 31055200
[TBL] [Abstract][Full Text] [Related]
7. Immunological classification of hepatitis B virus-positive hepatocellular carcinoma by transcriptome analysis.
Li SW; Han LF; He Y; Wang XS
World J Hepatol; 2022 Dec; 14(12):1997-2011. PubMed ID: 36618328
[TBL] [Abstract][Full Text] [Related]
8. Subtyping of head and neck squamous cell cancers based on immune signatures.
Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
[TBL] [Abstract][Full Text] [Related]
9. Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer.
Wang C; Bai R; Liu Y; Wang K; Wang Y; Yang J; Cai H; Yang P
Med Oncol; 2023 Jan; 40(2):78. PubMed ID: 36635412
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA-sequencing dissects cellular heterogeneity and identifies two tumor-suppressing immune cell subclusters in HPV-related cervical adenosquamous carcinoma.
Li X; Zhang M; Lei T; Zou W; Huang R; Wang F; Huang Q; Wang C; Liu C
J Med Virol; 2022 Dec; 94(12):6047-6059. PubMed ID: 36000446
[TBL] [Abstract][Full Text] [Related]
11. Association of Tumor Site With the Prognosis and Immunogenomic Landscape of Human Papillomavirus-Related Head and Neck and Cervical Cancers.
Zhu G; Amin N; Herberg ME; Maroun CA; Wang H; Guller M; Gourin CG; Rooper LM; Vosler PS; Tan M; D'Souza G; Koch WM; Eisele DW; Seiwert TY; Fakhry C; Pardoll DM; Mandal R
JAMA Otolaryngol Head Neck Surg; 2022 Jan; 148(1):70-79. PubMed ID: 34792560
[TBL] [Abstract][Full Text] [Related]
12. Integrated analysis of HPV-mediated immune alterations in cervical cancer.
Chen L; Luan S; Xia B; Liu Y; Gao Y; Yu H; Mu Q; Zhang P; Zhang W; Zhang S; Wei G; Yang M; Li K
Gynecol Oncol; 2018 May; 149(2):248-255. PubMed ID: 29572030
[TBL] [Abstract][Full Text] [Related]
13. Identification of HPV16 positive cervical cancer subsets characterized by divergent immune and oncogenic phenotypes with potential implications for immunotherapy.
Ghosh A; Ghosh A; Sinha A; Mathai S; Bhaumik J; Mukhopadhyay A; Maitra A; Biswas NK; Majumder PP; Sengupta S
Tumour Biol; 2023; 45(1):55-69. PubMed ID: 37599552
[TBL] [Abstract][Full Text] [Related]
14. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
15. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma.
Liu Q; Nie R; Li M; Li L; Zhou H; Lu H; Wang X
Comput Struct Biotechnol J; 2021; 19():4472-4485. PubMed ID: 34471493
[TBL] [Abstract][Full Text] [Related]
16. Identification of Breast Cancer Immune Subtypes by Analyzing Bulk Tumor and Single Cell Transcriptomes.
Yao J; Li S; Wang X
Front Cell Dev Biol; 2021; 9():781848. PubMed ID: 35047498
[No Abstract] [Full Text] [Related]
17. Involvement of the Toll-Like Receptor/Nitric Oxide Signaling Pathway in the Pathogenesis of Cervical Cancer Caused by High-Risk Human Papillomavirus Infection.
Li J; Rao H; Jin C; Liu J
Biomed Res Int; 2017; 2017():7830262. PubMed ID: 28626766
[TBL] [Abstract][Full Text] [Related]
18. Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers.
Wang Y; He M; He T; Ouyang X; Shen X; Shi W; Huang S; Xiang L; Zou D; Jiang W; Yang H
Br J Cancer; 2024 Apr; 130(6):987-1000. PubMed ID: 38253702
[TBL] [Abstract][Full Text] [Related]
19. Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.
Huang L; Liu X; Li L; Wang L; Wu N; Liu Z
Med Oncol; 2022 May; 39(5):92. PubMed ID: 35568771
[TBL] [Abstract][Full Text] [Related]
20. Identification of prostate cancer subtypes based on immune signature scores in bulk and single-cell transcriptomes.
Chen C; Luo J; Wang X
Med Oncol; 2022 Jun; 39(9):123. PubMed ID: 35716212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
